![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Primary Data Analyses of MAESTRO-NAFLD-1:a 52-week
Double-blind, Placebo-controlled Phase 3 Clinical
Trial of Resmetirom in Patients With NAFLD
|
|
|
EASL 2022 June 22-26 London
Stephen A. Harrison,1 Rebecca A. Taub,2 Guy W. Neff,3 Sam Moussa,4 Naim Alkhouri,5 Mustafa R. Bashir6
1University of Oxford, UK; Pinnacle Clinical Research, San Antonio, TX, USA; 2Madrigal Pharmaceuticals, Conshohocken, PA, USA; 3Covenant Metabolic Specialists, Sarasota, FL, USA; 4University of Arizona College of Medicine, Tucson, AZ, USA; 5Arizona Liver Health, Tucson AZ, USA; 6Duke University Medical Center, Durham, NC, USA
![0627221](../images/062822/062722-9/0627221.gif)
![0627222](../images/062822/062722-9/0627222.gif)
![0627223](../images/062822/062722-9/0627223.gif)
![0627224](../images/062822/062722-9/0627224.gif)
![0627225](../images/062822/062722-9/0627225.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|